Celltrion is expanding its product portfolio with the launch of the 300mg version of Omliclo (ingredient name: omalizumab) in major European countries, aimed at treating chronic spontaneous urticaria and allergic asthma.
On August 25, Celltrion announced that Omliclo has secured a competitive edge as the first-mover omalizumab biosimilar in Europe, and the company plans to leverage its broad product portfolio to enhance market influence and accelerate sales.
Omliclo is a biosimilar of omalizumab, which inhibits immunoglobulin E (IgE) involved in allergic reactions. It is also the first approved 'first-mover' product among omalizumab biosimilars in Europe.
Following the launch of Omliclo (75mg and 150mg) in Europe at the end of last year, Celltrion introduced the 300mg version in key countries such as Germany, the UK, and France starting mid-year. The 300mg version is currently being supplied in the countries where it has been launched, and Celltrion plans to expand its sales area across Europe. This proactive expansion aims to increase the availability of Omliclo 300mg compared to the original 300mg, which is only supplied in select countries.
The launch of Omliclo 300mg is significant as it enhances convenience for patients and treatment options for healthcare providers. Patients requiring a 300mg dose previously had to receive two injections of the 150mg dose, but with the single 300mg dose, treatment can be administered in one injection.
Additionally, Celltrion is offering Omliclo 300mg in both pre-filled syringes (PFS) and auto-injectors (AI), broadening the choices available to patients and healthcare providers. This allows for selection based on patient condition, administration environment, and usage method.
Omliclo 300mg also boasts competitive advantages in terms of safety and ease of use. It can be stored for up to two years under refrigeration (2-8°C) and for up to seven days at room temperature, providing a longer shelf life than the original product. Furthermore, it features a re-refrigeration capability, allowing it to be refrigerated again after being stored at room temperature, thus offering efficiency and flexibility during transportation, storage, and usage.
Hah Tae-hoon, head of Celltrion's European headquarters, stated, "With the launch of Omliclo 300mg, we can provide more convenient and diverse treatment options for patients and healthcare providers. We will do our utmost to ensure that Omliclo continues its rapid growth across Europe, leveraging the first-mover market advantage and our extensive product lineup."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.